Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01606410
Other study ID # IRI-IPC-aging
Secondary ID
Status Completed
Phase N/A
First received May 23, 2012
Last updated November 19, 2013
Start date April 2011
Est. completion date November 2013

Study information

Verified date November 2013
Source Radboud University
Contact n/a
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Observational

Clinical Trial Summary

Rationale: Ischaemic preconditioning (IP) refers to the reduction of ischemia-reperfusion injury induced by a brief preceding period of ischemia. Also the arterial endothelium can be protected by IP. Several studies performed in animals and humans have demonstrated that the protective effects of IP are attenuated with aging. However, no previous study directly examined the underlying mechanisms of this observation. Possibly, the reduced protective effect of IP with aging relates to a direct effect on the endothelium, consequently leading to an attenuated ability of IP to prevent endothelial dysfunction after ischaemia reperfusion injury.

Several previous studies failed to demonstrate the ability of pharmacological stimuli to mimic the beneficial effects of IP in aged vessels. Restoration of the age-related reduction in effectiveness of IP may be possible through exercise training. In aged animals, physical training restores the efficacy of ischemic preconditioning. Indirect evidence indicates that physical activity, independent of other cardiovascular risk factors, protects against a occurrence as well as the severity of a myocardial infarction in humans. Although this suggests that physical activity may beneficially influence the age-related reduction in IP, no previous study provided direct evidence for this hypothesis.

Objective: To examine the impact of age and physical fitness on the ability of ischaemic preconditioning to protect endothelial damage in response to ischaemia reperfusion injury in healthy humans. A secondary objective is to explore the role of Toll-like receptor (TLR) signalling in the induction of IP in young and old subjects.


Description:

Cardiovascular disease has become a worldwide burden. In the Netherlands over 40.000 persons die annually due to coronary artery disease, either acute myocardial infarction or heart failure.1 Through plaque formation and negative vascular remodelling, significant stenotic lesions develop in the coronary arteries that subsequently limit coronary blood flow and ultimately can cause ischemic events. Reperfusion therapy (either pharmacologic, endovascular or surgical) is mandatory for salvage of ischemic tissue. However, during reperfusion several deleterious events take place causing further damage. Murry found that ischemia and reperfusion injury (IR-injury) could be reduced by a phenomenon called ischemic preconditioning.2 Short lasting repetitive episodes of ischemia prior to an ischemic event can induce tissue tolerance against IR-injury.

After discovery of this phenomenon, ample research has been devoted to elucidation of the underling protective mechanism, but also factors that improve or impair the ability of this phenomenon to protect arteries against ischaemia reperfusion injury. Several studies performed in animals and humans have demonstrated that the protective effects of IP are attenuated with aging. Much of this work has been performed in animal models or in human in vitro studies. Interestingly, no previous study directly examined the underlying mechanisms of this observation in humans using in vivo techniques. One potential explanation for an age-related reduction of the protective effect of IP relates to a direct effect on the endothelium.

Much scientific effort has been devoted to develop a human in vivo model to study ischemia and reperfusion injury. Recently, publications emerged using the flow mediated dilation (FMD) of the brachial or radial artery before and after a sustained ischaemic stimulus (20 minutes) to establish the presence of a blunted endothelial function after ischaemia reperfusion injury.3, 4 This effect of reperfusion injury on the endothelial function can be abrogated by ischemic preconditioning.3 Endothelial dysfunction is acknowledged to be the first (subclinical) manifestation of atherosclerosis and cardiovascular disease.5, 6 It is significantly correlated to occurrence of myocardial infarction and stroke.6 Assessment of the flow mediated dilation of the brachial artery as measure of endothelial (dys)function, is a validated model to research effects of possible protective strategies3, 4 and perform mechanistic experiments4, 7, 8 on IR-injury in humans in vivo.

Several previous studies failed to demonstrate the ability of pharmacological stimuli to mimic the beneficial effects of IP in aging vessels.9 Restoration of the age-related reduction in effectiveness of IP may be possible through exercise training. Indirect evidence indicates that physical activity, independent of other cardiovascular risk factors, protects against an occurrence as well as the severity of a myocardial infarction in humans.10 Although this suggests that physical activity may beneficially influence the age-related reduction in IP, no previous study provided direct evidence for this hypothesis in humans.

In this cross-sectional observational experiment we will study the impact of aging (young versus older subjects) and physical fitness (sedentary versus trained older subjects) on the protective effects of ischaemic preconditioning on brachial artery endothelial function after ischaemia-reperfusion injury in healthy humans in vivo.

We hypothesize that aging is associated with an attenuated ability of ischaemic preconditioning to prevent the decrease in brachial artery endothelial function observed after ischaemia reperfusion injury. Moreover, we expect that the age-related reduction in effectiveness of ischaemic preconditioning to prevent endothelial dysfunction after reperfusion injury is (at least partly) preserved in trained older subjects.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date November 2013
Est. primary completion date November 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Healthy young volunteers : age 18-30

- Healthy older volunteers: age >55 years

- Sedentary: <1 h exercise per week

- Trained: >5 h exercise per week

- All subjects: written informed consent

Exclusion Criteria:

- Smoking

- History of any cardiovascular disease

- Hypertension (in supine position: systole >140 mmHg, diastole >90 mmHg)

- Diabetes Mellitus (fasting glucose >7.0 mmol/L or random glucose >11.0 mmol/L)

- Hyperlipidaemia (fasting total cholesterol >6.5 mmol/L)

- Chronic use of medication known to interfere with the cardiovascular system

- Professional athletes

- BMI >30 kg/m2

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional


Intervention

Other:
IPC
repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)

Locations

Country Name City State
Netherlands Department of Physiology Nijmegen

Sponsors (1)

Lead Sponsor Collaborator
Radboud University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary endothelial reperfusion injury Change in endothelial function (measured with flow mediated dilation) after ischaemia reperfusion injury (induced by 20 minutes ischemia) with and without precedence of ischaemic preconditioning (by 3 cycles of 5-minutes of ischaemia). cross-sectional observation (single time point) No
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT02502812 - Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects Phase 1
Recruiting NCT04216342 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers Phase 1
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT03646656 - Heart Health Buddies: Peer Support to Decrease CVD Risk N/A
Completed NCT02081066 - Identification of CETP as a Marker of Atherosclerosis N/A
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT03095261 - Incentives in Cardiac Rehabilitation N/A
Completed NCT02868710 - Individual Variability to Aerobic Exercise Training N/A
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Completed NCT02589769 - Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Recruiting NCT02885792 - Coronary Artery Disease in Patients Suffering From Schizophrenia N/A
Completed NCT02640859 - Investigation of Metabolic Risk in Korean Adults
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Completed NCT02272946 - Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk Phase 2
Completed NCT02657382 - Mental Stress Ischemia: Biofeedback Study N/A
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment